Quest Diagnostics (DGX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Quest Diagnostics (DGX) do?
Quest Diagnostics Inc (DGX) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Performs clinical laboratory testing, routine blood screenings, and specialized diagnostic procedures for patients and healthcare providers. Operates an expansive laboratory network serving one in three American adults across the country each year. It is worth $28.50B on the market and sold $11.83B over the last year.
- Market cap
- $28.50B
- P/E ratio
- 25.8×
- Annual sales
- $11.83B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 16, 2026
Brands and businesses behind DGX
- Quest Health: Sells direct to consumer lab tests and screenings online without requiring an initial doctor visit.
- Haystack Oncology: Provides minimal residual disease testing to detect lingering cancer cells using personalized liquid biopsy technology.
- AD-Detect: Offers blood tests that measure amyloid proteins to help assess personal risk for Alzheimer disease.
DGX’s flags, in plain English
Each flag is a number from Quest Diagnostics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Stupid Cash
Can pay this year's bills 1.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Earns Its Keep
Earns 15.1% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Growth Cooling
Sales growth slowed to 3.2% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.
Questions about DGX
How big is Quest Diagnostics?
Quest Diagnostics’ market cap is $28.50B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $11.83B: what customers paid the company over the last year, before any costs.
What is DGX’s P/E ratio?
DGX’s P/E ratio is 25.8×. Investors pay about 25.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with DGX?
Pending Medicare fee reductions threaten payment rates across high-volume routine diagnostic tests. That is one risk on Quest Diagnostics’ card. Its first risk flag is Growth Cooling, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Quest Diagnostics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. DGX’s filings on SEC.gov. The Margin Monkey is research, not advice.
